Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

High level of circulating vitamin D during neoadjuvant therapy may lower risk of metastatic progression in high-risk rectal cancer.

Abrahamsson H, Porojnicu AC, Lindstrøm JC, Dueland S, Flatmark K, Hole KH, Seierstad T, Moan J, Redalen KR, Meltzer S, Ree AH.

BMC Cancer. 2019 May 23;19(1):488. doi: 10.1186/s12885-019-5724-z.

2.

Towards personalized computer simulation of breast cancer treatment: a multi-scale pharmacokinetic and pharmacodynamic model informed by multi-type patient data.

Lai X, Geier OM, Fleischer T, Garred Ø, Borgen E, Funke SW, Kumar S, Rognes ME, Seierstad T, Børressen-Dale AL, Kristensen VN, Engebråten O, Köhn-Luque A, Frigessi A.

Cancer Res. 2019 May 22. pii: canres.1804.2018. doi: 10.1158/0008-5472.CAN-18-1804. [Epub ahead of print]

PMID:
31118201
3.

PTEN Expression in Prostate Cancer: Relationship With Clinicopathologic Features and Multiparametric MRI Findings.

Switlyk MD, Salberg UB, Geier OM, Vlatkovic L, Lilleby W, Lyng H, Seierstad T.

AJR Am J Roentgenol. 2019 Mar 19:1-9. doi: 10.2214/AJR.18.20743. [Epub ahead of print]

PMID:
30888866
4.

Local failure is a dominant mode of recurrence in locally advanced and clinical node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy.

Hayman J, Hole KH, Seierstad T, Perin J, DeWeese TL, Tran PT, Lilleby W.

Urol Oncol. 2019 Apr;37(4):289.e19-289.e26. doi: 10.1016/j.urolonc.2018.09.016. Epub 2018 Nov 13.

PMID:
30446451
5.

Localization of radio-recurrence within the prostate: anti-3-18F-FACBC PET/CT compared with multiparametric MRI using histopathology as reference standard.

Tulipan AJ, Hole KH, Vlatkovic L, Revheim ME, Reijnen JS, Willoch F, Seierstad T, Lilleby W.

Acta Radiol. 2018 Oct 31:284185118810977. doi: 10.1177/0284185118810977. [Epub ahead of print]

PMID:
30379559
6.

Markers of Mitochondrial Metabolism in Tumor Hypoxia, Systemic Inflammation, and Adverse Outcome of Rectal Cancer.

Bousquet PA, Meltzer S, Sønstevold L, Esbensen Y, Dueland S, Flatmark K, Sitter B, Bathen TF, Seierstad T, Redalen KR, Eide L, Ree AH.

Transl Oncol. 2019 Jan;12(1):76-83. doi: 10.1016/j.tranon.2018.09.010. Epub 2018 Sep 29.

7.

Combined MR Imaging of Oxygen Consumption and Supply Reveals Tumor Hypoxia and Aggressiveness in Prostate Cancer Patients.

Hompland T, Hole KH, Ragnum HB, Aarnes EK, Vlatkovic L, Lie AK, Patzke S, Brennhovd B, Seierstad T, Lyng H.

Cancer Res. 2018 Aug 15;78(16):4774-4785. doi: 10.1158/0008-5472.CAN-17-3806. Epub 2018 Jun 26.

PMID:
29945958
8.

Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer.

Kalanxhi E, Meltzer S, Schou JV, Larsen FO, Dueland S, Flatmark K, Jensen BV, Hole KH, Seierstad T, Redalen KR, Nielsen DL, Ree AH.

Br J Cancer. 2018 May;118(10):1322-1328. doi: 10.1038/s41416-018-0085-y. Epub 2018 Apr 26.

9.

18F-FDG PET/CT for the quantification of inflammation in large carotid artery plaques.

Johnsrud K, Skagen K, Seierstad T, Skjelland M, Russell D, Revheim ME.

J Nucl Cardiol. 2019 Jun;26(3):883-893. doi: 10.1007/s12350-017-1121-7. Epub 2017 Dec 5.

10.

Growth rates of pulmonary metastases after liver transplantation for unresectable colorectal liver metastases.

Grut H, Solberg S, Seierstad T, Revheim ME, Egge TS, Larsen SG, Line PD, Dueland S.

Br J Surg. 2018 Feb;105(3):295-301. doi: 10.1002/bjs.10651. Epub 2017 Nov 23.

PMID:
29168565
11.

GPs' and child and adolescent psychiatry specialists' experiences of joint consultations in the GP's office: a qualitative study.

Seierstad TG, Brekke M, Toftemo I, Haavet OR.

BMC Res Notes. 2017 Sep 7;10(1):458. doi: 10.1186/s13104-017-2766-7.

12.

Diffusion-weighted magnetic resonance imaging of rectal cancer: tumour volume and perfusion fraction predict chemoradiotherapy response and survival.

Bakke KM, Hole KH, Dueland S, Grøholt KK, Flatmark K, Ree AH, Seierstad T, Redalen KR.

Acta Oncol. 2017 Jun;56(6):813-818. doi: 10.1080/0284186X.2017.1287951. Epub 2017 Feb 17.

PMID:
28464745
13.

Molecular lipid species in urinary exosomes as potential prostate cancer biomarkers.

Skotland T, Ekroos K, Kauhanen D, Simolin H, Seierstad T, Berge V, Sandvig K, Llorente A.

Eur J Cancer. 2017 Jan;70:122-132. doi: 10.1016/j.ejca.2016.10.011. Epub 2016 Nov 30.

PMID:
27914242
14.

Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition.

Jonsson M, Ragnum HB, Julin CH, Yeramian A, Clancy T, Frikstad KM, Seierstad T, Stokke T, Matias-Guiu X, Ree AH, Flatmark K, Lyng H.

Br J Cancer. 2016 Oct 11;115(8):929-939. doi: 10.1038/bjc.2016.278. Epub 2016 Sep 6.

15.

Individual tumor volume responses to short-course oxaliplatin-containing induction chemotherapy in locally advanced rectal cancer - Targeting the tumor for radiation sensitivity?

Flatmark K, Saelen MG, Hole KH, Abrahamsen TW, Fleten KG, Hektoen HH, Redalen KR, Seierstad T, Dueland S, Ree AH.

Radiother Oncol. 2016 Jun;119(3):505-11. doi: 10.1016/j.radonc.2016.02.020. Epub 2016 Mar 8.

PMID:
26968754
16.

Oxaliplatin-containing Preoperative Therapy in Locally Advanced Rectal Cancer: Local Response, Toxicity and Long-term Outcome.

Dueland S, Ree AH, Grøholt KK, Saelen MG, Folkvord S, Hole KH, Seierstad T, Larsen SG, Giercksky KE, Wiig JN, Boye K, Flatmark K.

Clin Oncol (R Coll Radiol). 2016 Aug;28(8):532-9. doi: 10.1016/j.clon.2016.01.014. Epub 2016 Feb 14.

PMID:
26888115
17.

High tumor glycine concentration is an adverse prognostic factor in locally advanced rectal cancer.

Redalen KR, Sitter B, Bathen TF, Grøholt KK, Hole KH, Dueland S, Flatmark K, Ree AH, Seierstad T.

Radiother Oncol. 2016 Feb;118(2):393-8. doi: 10.1016/j.radonc.2015.11.031. Epub 2015 Dec 17.

18.

Identification of prostate cancer biomarkers in urinary exosomes.

Øverbye A, Skotland T, Koehler CJ, Thiede B, Seierstad T, Berge V, Sandvig K, Llorente A.

Oncotarget. 2015 Oct 6;6(30):30357-76. doi: 10.18632/oncotarget.4851.

19.

MRI volumetry for prediction of tumour response to neoadjuvant chemotherapy followed by chemoradiotherapy in locally advanced rectal cancer.

Seierstad T, Hole KH, Grøholt KK, Dueland S, Ree AH, Flatmark K, Redalen KR.

Br J Radiol. 2015 Jul;88(1051):20150097. doi: 10.1259/bjr.20150097. Epub 2015 Apr 22.

20.
21.

The tumour hypoxia marker pimonidazole reflects a transcriptional programme associated with aggressive prostate cancer.

Ragnum HB, Vlatkovic L, Lie AK, Axcrona K, Julin CH, Frikstad KM, Hole KH, Seierstad T, Lyng H.

Br J Cancer. 2015 Jan 20;112(2):382-90. doi: 10.1038/bjc.2014.604. Epub 2014 Dec 2.

22.

Dynamic (18) F-FDG PET for Assessment of Tumor Physiology in Two Breast Carcinoma Xenografts.

Kristian A, Nilsen LB, Røe K, Revheim ME, Engebråten O, Mælandsmo GM, Holm R, Malinen E, Seierstad T.

Nucl Med Mol Imaging. 2013 Sep;47(3):173-80. doi: 10.1007/s13139-013-0211-y. Epub 2013 Jun 21.

23.

Standardized cine-loop documentation in renal ultrasound facilitates skill-mix between radiographer and radiologist.

Gaarder M, Seierstad T, Søreng R, Drolsum A, Begum K, Dormagen JB.

Acta Radiol. 2015 Mar;56(3):368-73. doi: 10.1177/0284185114527868. Epub 2014 Mar 10.

PMID:
24615418
24.

Diffusion-weighted MRI compared to FDG PET/CT for assessment of early treatment response in lymphoma.

Hagtvedt T, Seierstad T, Lund KV, Løndalen AM, Bogsrud TV, Smith HJ, Geier OM, Holte H, Aaløkken TM.

Acta Radiol. 2015 Feb;56(2):152-8. doi: 10.1177/0284185114526087. Epub 2014 Feb 28.

PMID:
24585944
25.

Radiotherapy for spinal metastases from breast cancer with emphasis on local disease control and pain response using repeated MRI.

Switlyk MD, Bruland ØS, Skjeldal S, Hald JK, Seierstad T, Zaikova O.

J Bone Oncol. 2014 Mar 12;3(1):5-9. doi: 10.1016/j.jbo.2014.02.003. eCollection 2014 Mar.

26.

Associations between tumor vascularization assessed by in vivo DCE-MRI and the presence of disseminated tumor cells in bone marrow in breast cancer patients at the time of diagnosis.

Nilsen LB, Fangberget A, Geier OM, Engebraaten O, Borgen E, Olsen DR, Seierstad T.

J Magn Reson Imaging. 2014 Dec;40(6):1382-91. doi: 10.1002/jmri.24502. Epub 2014 Jan 27.

PMID:
24470360
27.

Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer.

Ragnum HB, Røe K, Holm R, Vlatkovic L, Nesland JM, Aarnes EK, Ree AH, Flatmark K, Seierstad T, Lilleby W, Lyng H.

Int J Radiat Oncol Biol Phys. 2013 Nov 15;87(4):753-60. doi: 10.1016/j.ijrobp.2013.07.023. Epub 2013 Sep 10.

PMID:
24035332
28.

Dynamic (18)F-FDG-PET for monitoring treatment effect following anti-angiogenic therapy in triple-negative breast cancer xenografts.

Kristian A, Revheim ME, Qu H, Mælandsmo GM, Engebråten O, Seierstad T, Malinen E.

Acta Oncol. 2013 Oct;52(7):1566-72. doi: 10.3109/0284186X.2013.813634. Epub 2013 Aug 29.

PMID:
23984812
29.

Multimodal functional imaging for early response assessment in GIST patients treated with imatinib.

Revheim ME, Hole KH, Bruland OS, Reitan E, Bjerkehagen B, Julsrud L, Seierstad T.

Acta Oncol. 2014 Jan;53(1):143-8. doi: 10.3109/0284186X.2013.798428. Epub 2013 May 28. No abstract available.

30.

Intermittent and continuous imatinib in a human GIST xenograft model carrying KIT exon 17 resistance mutation D816H.

Revheim ME, Kristian A, Malinen E, Bruland ØS, Berner JM, Holm R, Joensuu H, Seierstad T.

Acta Oncol. 2013 May;52(4):776-82. doi: 10.3109/0284186X.2013.770920. Epub 2013 Mar 13.

31.

Routine pelvic MRI using phased-array coil for detection of extraprostatic tumour extension: accuracy and clinical significance.

Hole KH, Axcrona K, Lie AK, Vlatkovic L, Geier OM, Brennhovd B, Knutstad K, Olsen DR, Seierstad T.

Eur Radiol. 2013 Apr;23(4):1158-66. doi: 10.1007/s00330-012-2669-x. Epub 2012 Nov 1.

32.

Quantitative analysis of diffusion-weighted magnetic resonance imaging in malignant breast lesions using different b value combinations.

Nilsen LB, Fangberget A, Geier O, Seierstad T.

Eur Radiol. 2013 Apr;23(4):1027-33. doi: 10.1007/s00330-012-2687-8. Epub 2012 Oct 31.

33.

MRI and neurological findings in patients with spinal metastases.

Switlyk MD, Hole KH, Skjeldal S, Hald JK, Knutstad K, Seierstad T, Zaikova O.

Acta Radiol. 2012 Dec 1;53(10):1164-72. doi: 10.1258/ar.2012.120442. Epub 2012 Oct 9.

PMID:
23047848
34.

Reject analysis in direct digital radiography.

Andersen ER, Jorde J, Taoussi N, Yaqoob SH, Konst B, Seierstad T.

Acta Radiol. 2012 Mar 1;53(2):174-8. doi: 10.1258/ar.2011.110350. Epub 2012 Jan 27.

PMID:
22287147
35.

Radiation doses to Norwegian heart-transplanted patients undergoing annual coronary angiography.

Seierstad T, Friberg EG, Lervåg C, Widmark A, Wilhelmsen N, Stranden E.

Radiat Prot Dosimetry. 2012 May;149(4):403-9. doi: 10.1093/rpd/ncr311. Epub 2011 Jul 20.

PMID:
21775318
36.

Early prediction of response to radiotherapy and androgen-deprivation therapy in prostate cancer by repeated functional MRI: a preclinical study.

Røe K, Kakar M, Seierstad T, Ree AH, Olsen DR.

Radiat Oncol. 2011 Jun 8;6:65. doi: 10.1186/1748-717X-6-65.

37.

G-CSF enhances the proliferation and mobilization, but not the maturation rate, of murine myeloid cells.

Knudsen E, Iversen PO, Bøyum A, Seierstad T, Nicolaysen G, Benestad HB.

Eur J Haematol. 2011 Oct;87(4):302-11. doi: 10.1111/j.1600-0609.2011.01658.x. Epub 2011 Jul 26.

PMID:
21623923
38.
39.

Monitoring the effect of targeted therapies in a gastrointestinal stromal tumor xenograft using a clinical PET/CT.

Revheim ME, Røe K, Bruland ØS, Bach-Gansmo T, Skretting A, Seierstad T.

Mol Imaging Biol. 2011 Dec;13(6):1234-40. doi: 10.1007/s11307-010-0464-0.

40.

Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging.

Fangberget A, Nilsen LB, Hole KH, Holmen MM, Engebraaten O, Naume B, Smith HJ, Olsen DR, Seierstad T.

Eur Radiol. 2011 Jun;21(6):1188-99. doi: 10.1007/s00330-010-2020-3. Epub 2010 Dec 3.

41.

DW MRI for evaluation of treatment response to imatinib in a rectal gastrointestinal stromal tumour.

Revheim ME, Hole KH, Bruland OS, Haugland HK, Hall KS, Seierstad T.

Acta Oncol. 2011 Jan;50(1):148-50. doi: 10.3109/0284186X.2010.516273. Epub 2010 Nov 29. No abstract available.

PMID:
21110775
42.
43.

Preclinical dynamic 18F-FDG PET - tumor characterization and radiotherapy response assessment by kinetic compartment analysis.

Røe K, Aleksandersen TB, Kristian A, Nilsen LB, Seierstad T, Qu H, Ree AH, Olsen DR, Malinen E.

Acta Oncol. 2010 Oct;49(7):914-21. doi: 10.3109/0284186X.2010.498831.

PMID:
20831478
44.
45.

Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study.

Ree AH, Dueland S, Folkvord S, Hole KH, Seierstad T, Johansen M, Abrahamsen TW, Flatmark K.

Lancet Oncol. 2010 May;11(5):459-64. doi: 10.1016/S1470-2045(10)70058-9. Epub 2010 Apr 6.

PMID:
20378407
46.

Establishment and characterization of a human gastrointestinal stromal tumour (GIST) xenograft in athymic nude mice.

Revheim ME, Seierstad T, Berner JM, Bruland OS, Røe K, Ohnstad HO, Bjerkehagen B, Bach-Gansmo T.

Anticancer Res. 2009 Nov;29(11):4331-6.

47.

MR-guided simultaneous integrated boost in preoperative radiotherapy of locally advanced rectal cancer following neoadjuvant chemotherapy.

Seierstad T, Hole KH, Saelen E, Ree AH, Flatmark K, Malinen E.

Radiother Oncol. 2009 Nov;93(2):279-84. doi: 10.1016/j.radonc.2009.08.046. Epub 2009 Oct 1.

PMID:
19800704
48.

Artificial neural networks for prediction of response to chemoradiation in HT29 xenografts.

Kakar M, Seierstad T, Røe K, Olsen DR.

Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):506-11. doi: 10.1016/j.ijrobp.2009.05.036.

PMID:
19735875
49.

Assessing quality of life in a randomized clinical trial: correcting for missing data.

Gunnes N, Seierstad TG, Aamdal S, Brunsvig PF, Jacobsen AB, Sundstrøm S, Aalen OO.

BMC Med Res Methodol. 2009 Apr 30;9:28. doi: 10.1186/1471-2288-9-28.

50.

Analysis of censored discrete longitudinal data: estimation of mean response.

Gunnes N, Farewell DM, Seierstad TG, Aalen OO.

Stat Med. 2009 Feb 15;28(4):605-24. doi: 10.1002/sim.3492.

PMID:
19035531

Supplemental Content

Loading ...
Support Center